Search company, investor...
Search

Predict your next investment

Venture Capital
deloscapital.com

See what CB Insights has to offer

Investments

19

Portfolio Exits

2

About Delos Capital

Delos Capital is a healthcare-focused fund, investing in growth platforms in Greater China and relevant innovation in the US in both therapeutics and medical technology areas. Delos Capital seeks to achieve returns through supporting these companies in their development and also helping to create additional value from collaboration between these companies.

Delos Capital Headquarters Location

19/F Fung House 19 – 20 Connaught Road Central

Hong Kong

+852-3912-0500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Delos Capital News

Wynnchurch Capital Acquires FCA Packaging from Delos

Aug 16, 2022

Wynnchurch Capital has acquired FCA Packaging, a maker of industrial protective packaging, from Delos Capital and Brookside Capital Partners. FCA Packaging is a manufacturer of customized and heavy-duty industrial packaging products including skids, crates, pallets, and collapsible boxes made from numerous material types including wood, steel, corrugated and hybrid packaging. The company’s products are used... […]

Delos Capital Investments

19 Investments

Delos Capital has made 19 investments. Their latest investment was in Antios Therapeutics as part of their Series B - II on November 11, 2021.

CBI Logo

Delos Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/3/2021

Series B - II

Antios Therapeutics

$75M

No

11

7/15/2021

Series D

Imperative Care

$260M

Yes

14

5/26/2021

Series A

LifeQ

$47M

Yes

9

5/6/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

4/12/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/3/2021

7/15/2021

5/26/2021

5/6/2021

4/12/2021

Round

Series B - II

Series D

Series A

Series B

Series B

Company

Antios Therapeutics

Imperative Care

LifeQ

Subscribe to see more

Subscribe to see more

Amount

$75M

$260M

$47M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

11

14

9

10

10

Delos Capital Portfolio Exits

2 Portfolio Exits

Delos Capital has 2 portfolio exits. Their latest portfolio exit was Apama Medical on October 02, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/2/2017

Acquired

$99M

2

3/3/2016

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/2/2017

3/3/2016

Exit

Acquired

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

2

10

Delos Capital Team

2 Team Members

Delos Capital has 2 team members, including current Founder, Managing Partner, Henry Chen.

Name

Work History

Title

Status

Henry Chen

Permira, Goldman Sachs, and Davis Polk & Wardwell

Founder, Managing Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Henry Chen

Subscribe to see more

Work History

Permira, Goldman Sachs, and Davis Polk & Wardwell

Title

Founder, Managing Partner

Subscribe to see more

Status

Current

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.